Keyphrases
17-estradiol
100%
18F-FES
35%
18F-FES PET
50%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
7%
Breast Cancer Research
7%
Clinical Decision-making
7%
Endocrine Therapy
100%
Estrogen Receptor
71%
Estrogen Receptor Status
7%
Estrogen Receptor-positive
7%
Estrogen Receptor-positive Metastatic Breast Cancer
100%
Fluoro
100%
Hazard Ratio
14%
Intra-patient
100%
Intrapatient Heterogeneity
7%
Large Cohort
14%
Large Lesions
21%
Lesion Assessment
7%
Lesion Method
14%
Manual Segmentation
14%
Median Overall Survival
7%
Median Progression-free Survival
7%
Metastasis
7%
Metastatic Breast Cancer
100%
Newly Diagnosed
7%
Overall Survival
14%
Positive Predictive Value
14%
Primary Endocrine Therapy
7%
Prognostic Factors
100%
Prognostic Value
7%
Progression-free Survival
14%
Therapy Response
100%
Visual Assessment
7%
Pharmacology, Toxicology and Pharmaceutical Science
16alpha Fluoroestradiol F 18
70%
Diethylstilbestrol
100%
Endocrine Therapy
100%
Estrogen Receptor
100%
Fluorine 18
100%
Fluorodeoxyglucose F 18
5%
Metastatic Breast Cancer
100%
Overall Survival
17%
Polyethylene Terephthalate
100%
Progression Free Survival
17%
Neuroscience
16alpha Fluoroestradiol F 18
80%
Clinical Decision Making
6%
Diethylstilbestrol
100%
Estrogen Receptor
100%
Fluorine-18
100%
Hormone Therapy
100%
Positron Emission Tomography
100%
Receptor Expression
6%